SNY
SNY clinical trials: Sanofi
Every trial on ClinicalTrials.gov where Sanofi is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 3,450
- Trials linked
- 2,327
- As lead sponsor
- 1,123
- As collaborator
- 19
- Primary completions as lead sponsor, next 90 days
SNY on the catalyst calendar · SNY registry changes
- Primary completion Jul 5, 2028Sponsor estimateNo phase registeredNCT06169527A Long-term Data Collection Study of Participants in France Aged 6 Years Old or More With Atopic Dermatitis Receiving DupilumabSanofi · Atopic DermatitisActive, not recruitingSNYLeadREGNCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 17, 2026Sponsor estimatePhase 2NCT06975722A Study to Investigate the Efficacy and Safety of Brivekimig in Adult Participants With Ulcerative ColitisSanofi · Ulcerative ColitisActive, not recruitingSNYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 17, 2026Sponsor estimatePhase 2NCT06958536A Study to Investigate Efficacy and Safety of Brivekimig in Participants With Crohn's DiseaseSanofi · Crohn's DiseaseRecruitingSNYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 23, 2031Sponsor estimatePhase 3NCT07793409A Study to Evaluate the Long-term Safety and Efficacy of Lunsekimig in Adult Participants With Chronic Obstructive Pulmonary Disease (COPD)Sanofi · Chronic Obstructive Pulmonary DiseaseEnrolling by invitationSNYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 27, 2029Sponsor estimatePhase 3NCT07190209Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic...Sanofi · Chronic Obstructive Pulmonary DiseaseRecruitingSNYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 31, 2028Sponsor estimatePhase 3NCT07086976A Study to Investigate the Efficacy, Safety, and Pharmacokinetics of Oral Rilzabrutinib Compared With Placebo in Participants 18 Years...Sanofi · Autoimmune Haemolytic AnaemiaRecruitingSNYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 20, 2031Sponsor estimatePhase 2NCT06609239Long-term Safety and Efficacy Evaluation of Lunsekimig (SAR443765) in Adult Participants With AsthmaSanofi · AsthmaEnrolling by invitationSNYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 9, 2027Sponsor estimatePhase 3NCT06290141A Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) in People With...Sanofi · Chronic Inflammatory Demyelinating PolyneuropathyRecruitingSNYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 13, 2027Sponsor estimatePhase 1/Phase 2NCT04643002Isatuximab in Combination With Novel Agents in RRMM - Master ProtocolSanofi · Plasma Cell Myeloma RefractoryRecruitingSNYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 12, 2026ActualNo phase registeredNCT04598893Recent-Onset Type 1 Diabetes Extension Study Evaluating the Long-Term Safety of Teplizumab (PROTECT Extension)Provention Bio, a Sanofi Company · Diabetes Mellitus, Type 1CompletedSNYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 31, 2034Sponsor estimateNo phase registeredNCT00358943International Collaborative Gaucher Group (ICGG) Gaucher Disease Registry & Pregnancy Sub-registryGenzyme, a Sanofi Company · Gaucher DiseaseRecruitingSNYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 31, 2034Sponsor estimateNo phase registeredNCT00196742Fabry Disease Registry & Pregnancy Sub-registryGenzyme, a Sanofi Company · Fabry DiseaseRecruitingSNYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 23, 2027Sponsor estimatePhase 3NCT06975865The Efficacy and Safety of Rilzabrutinib in Participants Aged 10 to 65 Years With Sickle-cell DiseaseSanofi · Sickle Cell DiseaseRecruitingSNYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 19, 2028Sponsor estimatePhase 1/Phase 2NCT07756957Safety of the Acne mRNA Vaccine in Adolescents 12 to 17 Years of Age With Moderate to Severe AcneSanofi · AcneRecruitingSNYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 15, 2027Sponsor estimatePhase 1NCT07944885First-in-human Study of SAR448632 in Healthy Adult ParticipantsSanofi · Healthy VolunteerNot yet recruitingSNYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 26, 2027Sponsor estimatePhase 1NCT07726914Study to Compare the Plasma Concentration of Belumosudil Given as an Oral Suspension and as a Tablet to Healthy Adult Male ParticipantsSanofi · Chronic Graft Versus Host DiseaseNot yet recruitingSNYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 6, 2028Sponsor estimatePhase 3NCT07088068A Study to Investigate Efficacy and Safety of Teplizumab Compared With Placebo in Participants 1 to 25 Years of Age With Stage 3 Type 1...Sanofi · Type 1 Diabetes MellitusRecruitingSNYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 27, 2026ActualNo phase registeredNCT04848779A Prospective Study to Observe & Describe Clinical Outcomes of Alglucosidase Alfa Treatment in Patients ≤6 Months of Age With...Sanofi · Glycogen Storage Disease Type IICompletedSNYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 10, 2035Sponsor estimatePhase 2/Phase 3NCT07923305Phase 2 and 3 Placebo Controlled & Long-term Extension Study of Rilzabrutinib in Adults With iCVID to Evaluate Efficacy, Safety, and...Sanofi · Immunodeficiency Common VariableNot yet recruitingSNYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 26, 2029Sponsor estimateNo phase registeredNCT07200206A Post-marketing Surveillance Study of Beyfortus (Nirsevimab) in Republic of KoreaSanofi · Respiratory Syncytial VirusRecruitingSNYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 7, 2026ActualNo phase registeredNCT06052800Agalsidase Beta Long-Term Treatment Outcome for Fabry Disease Patients With IVS4 Mutation in TaiwanSanofi · Fabry DiseaseCompletedSNYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 27, 2028Sponsor estimatePhase 3NCT07941622Study of Hexaxim Compared With Pentaxim Administered With a Monovalent Hepatitis B Vaccine in Healthy Chinese Infants.Sanofi · Haemophilus Influenzae Type b ImmunisationNot yet recruitingSNYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 16, 2031Sponsor estimatePhase 3NCT07930624A Study to Investigate Long-term Safety and Tolerability of Frexalimab in Participants With Multiple SclerosisSanofi · Multiple SclerosisNot yet recruitingSNYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 26, 2026Sponsor estimatePhase 4NCT07861542Study of a Recombinant Spike COVID-19 Vaccine With Matrix-M in Older Adults and People at Increased Risk of Severe COVID-19Sanofi · COVID-19Active, not recruitingSNYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 28, 2027Sponsor estimatePhase 3NCT07890454Study of a Combination SARS-CoV-2 Recombinant Spike and High-Dose Inactivated Influenza Vaccine With Matrix-M Adjuvant in Adult...Sanofi · ImmunizationRecruitingSNYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 25 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScannerShowing the first 25 trials. There are 3,425 more in this window; the full list is part of TrialScanner.
Unlock with TrialScanner